Table 2 Summary of the results from the univariate and multivariate COX proportional hazard model to determine factors influencing tamoxifen resistance in the HR+ breast cancer patients
Characteristic | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
All | ||||
Age (years) | ||||
< 50 | 1.344 (0.484–3.730) | 0.571 | ||
≥ 50 | ||||
Tumor size | ||||
T1 + T2 | 1.227 (0.407–3.696) | 0.716 | ||
T3 + T4 | ||||
Local lymph node metastasis | ||||
N0 | 1.300 (0.512–3.302) | 0.581 | ||
N1-N3 | ||||
TNM stage | ||||
I + II | 2.176 (0.884–5.356) | 0.091 | ||
III | ||||
Her-2 expression | ||||
Over express | 1.429 (0.563–3.630) | 0.453 | ||
Low express | ||||
Tumor classification | ||||
Luminal A | 0.396 (0.151–1.042) | 0.061 | ||
Luminal B + Her-2 overexpression (HR +) | ||||
-MENA expression | ||||
Low | 0.278 (0.112–0.693) | 0.006 | 0.268 (0.104–0.691) | 0.006 |
High | ||||